Doximity's core marketing niche is maturing, with revenue growth decelerating to 7.3% year-over-year in 2027Q1 from 23.2% in 2026Q2, while gross margins have eroded to 84.9% from a peak of 91.6%.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.36+3.4% vs $0.35 | $175M+2.2% vs $171M |
Q3 2026 Aug 6, 2026 | $0.29-4.3% vs $0.30 | $157M+3.2% vs $152M |
Q2 2026 May 13, 2026 | $0.26-7.1% vs $0.28 | $145M+0.9% vs $144M |
Q1 2026 Feb 5, 2026 | $0.46+4.5% vs $0.44 | $185M+1.9% vs $182M |
Doximity NYSE: DOCS reported fiscal second-quarter revenue growth of 4% and raised its full-year outlook, as expanding use of its artificial intelligence tools and improving AI cost efficiency helped the company exceed its guidance.
Doximity, Inc. ( DOCS ) Q2 2027 Earnings Call November 5, 2026 5:00 PM EST Company Participants Perry Gold - Head of Investor Relations Jeffrey Tangney - Co-Founder, CEO & Chairperson Matthew Sonefeldt - CFO & Principal Financial Officer Conference Call Participants Brian Peterson - Raymond James & Associates, Inc., Research Division Michael Cherny - Leerink Partners LLC, Research Division Craig Hettenbach - Morgan Stanley, Research Division Ryan Daniels - William Blair & Company L.L.C., Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Ryan MacDonald - Needham & Company, LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division Richard Close - Canaccord Genuity Corp., Research Division Jessica Tassan - Piper Sandler & Co., Research Division Destiny Ann Jackson - JPMorgan Chase & Co, Research Division Allen Lutz - BofA Securities, Research Division Ryan Halsted - RBC Capital Markets, Research Division Presentation Operator Hello, everyone.
Lawsuit alleges Doximity, Inc. made misleading statements to investors from August 8, 2024 to May 13, 2026; lead plaintiff motions are due November 16, 2026 LOS ANGELES, Oct. 27, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS) on behalf of investors who acquired the Company's securities from August 8, 2024 to May 13, 2026.
New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS) on behalf of investors that purchased or otherwise acquired Doximity common stock between August 8, 2024 and May 13, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Doximity and have suffered losses, you may CLICK HERE to contact us.
Benchmark DOCS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Doximity, Inc. (DOCS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $32.51 | $6.08B | 43.70 | 13.05% | 21.12% | 14.81% | — | |
| $26.00 | $5.8B | -42.42 | 59% | -5.51% | -30.03% | — | |
| $245.01 | $176.55B | 126.51 | 35.82% | 10.67% | 3.15% | 1.13% | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $303.73 | $49.34B | 49.40 | 16.34% | 29.34% | 14% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — |
Doximity, Inc. (DOCS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Doximity, Inc. (DOCS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 13, 2026·SEC
Apr 17, 2026·SEC
Get notified when DOCS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Doximity, Inc. (DOCS) stock FAQ — growth, dividends, profitability & financials explained
Doximity, Inc. (DOCS) reported $661.6M in revenue over the trailing twelve months. Revenue was $644.9M in fiscal year 2026. That is 653% more than the $85.7M of fiscal year 2019.
Doximity, Inc. (DOCS) grew revenue by 6.5% over the trailing twelve months, compared with the twelve months before.
Yes. Doximity, Inc. (DOCS) earned $139.7M in net income over the trailing twelve months (a 21.1% net margin).
Doximity, Inc. (DOCS) had a return on equity (ROE) of 14.8% over the trailing twelve months. That is in line with the market's typical 10-15%.
Doximity, Inc. (DOCS) generated $299.0M in free cash flow over the trailing twelve months.
